Bettina Hamelin

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.

Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London.